The Lao Daewoong version of Mobocertinib is an oral targeted drug for non-small cell lung cancer with EGFR exon 20 insertion mutation. It is a high-quality generic version launched by Daewoong Pharmaceutical in the ASEAN region, aiming to improve patient accessibility.
Is there a generic version of Mobocertinib from Laos?
Yes, there is a generic version of Mobocertinib from Laos. The Lao Daewoong version of Mobocertinib is available in the specification of 40mg*112 capsules/box. For more questions, it is recommended that you contact professional customer service for detailed consultation.
Approval background and basic information of Mobocertinib
Mobocertinib (development code: TAK-788, trade name: Mobocertinib) is an oral small molecule EGFR tyrosine kinase inhibitor independently developed by Takeda Pharmaceutical Company of Japan. On September 15, 2021, the U.S. Food and Drug Administration (FDA) approved Mobocertinib under accelerated approval based on clinical study data for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy, and who have confirmed EGFR exon 20 insertion mutation positivity by an FDA-approved test. This approval brought new hope to NSCLC patients with EGFR exon 20 insertion mutations, who have long lacked effective targeted therapy. The specification of Mobocertinib is 40mg×120 capsules, to be stored closed at room temperature (20°C-25°C) protected from moisture, and short-term storage at 15°C-30°C is permissible. As an important product of Takeda in the field of precision lung cancer therapy, the approval of Mobocertinib marks a breakthrough in the treatment of rare EGFR mutation subtypes.
Mechanism of action and target characteristics of Mobocertinib
The mechanism of action of Mobocertinib (TAK-788) is that it is an epidermal growth factor receptor (EGFR) kinase inhibitor that irreversibly binds to and inhibits EGFR exon 20 insertion mutations. Compared to wild-type EGFR, Mobocertinib shows higher affinity for EGFR exon 20 insertion mutations, with inhibitory concentrations lower than those for wild-type EGFR. After oral administration, two pharmacologically active metabolites, designated AP32960 and AP32914, with inhibition profiles similar to the parent drug, are detected in human plasma. In vitro studies have shown that at clinically relevant concentrations (IC50 values<2nm), mobocertinib="" also="" inhibits="" other="" egfr="" family="" members="">
